Mark A Cervinski, PhD
Title(s)
Associate Professor of Pathology and Laboratory Medicine
Additional Titles/Positions/Affiliations
Director of Clinical Chemistry
Director of Point-Of-Care Testing
Diplomate of the American Board of Clinical Chemistry
Fellow, AACC Academy
Department(s)
Pathology and Laboratory Medicine
Education
Ph.D. Biochemistry and Molecular Biology, 2006
University of North Dakota School of Medicine and Health Sciences
Clinical Chemistry Fellowship, 2007-2009
Washington University School of Medicine
Contact Information
Department of Pathology
Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon NH 03756
Phone: 603 650 7114
Fax: 603 650 4845
Email: mark.a.cervinski@hitchcock.org
Professional Interests
General Clinical Chemistry
Laboratory Test Utilization Management
Real Time Patient Based Quality Control
Human Chorionic Gonadotropin
Toxicology
Courses Taught
Director of ComACC Accredited Clinical Chemistry Fellowship Program
Lecturer for the Geisel School of Medicine General Pathology Course
Mentoring Information
Director of the Clinical Chemistry Fellowship program at DHMC
http://www.comacc.org/training/Pages/Dartmouth_Hitchcock.html
Biography
Mark Cervinski Ph.D DABCC, originally from Bonnyville, Alberta Canada received his Ph.D. in Biochemistry and Molecular Biology from the University of North Dakota in Grand Forks, North Dakota in 2006. Following his Ph.D. training Dr. Cervinski shifted his focus from the basic sciences to clinical chemistry and completed a Fellowship in Clinical Chemistry from Washington University in St. Louis in the summer of 2009. Mark joined the Department of Pathology and Laboratory Medicine as an Assistant Professor and as the Director of Clinical Chemistry at Dartmouth-Hitchcock Medical Center in August of 2009. Among diverse interests in clinical chemistry and laboratory medicine Dr. Cervinski is currently focused on using patient data as a supplementary quality control strategy, as well as test utilization/optimization and finding efficiencies in delivering laboratory results.
Immunologic investigation of an allergic transfusion reaction suspected due to alpha-gal syndrome. Evaluation of Immunoassay Performance for the Detection of Opioids in Urine. Commentary on Negative Sweat Chloride Testing in the Setting of a Positive Newborn Screen and CFTR Compound Heterozygosity. Fundamental Uncertainty: Interplatform Inconsistency of FDA-Cleared Serological Tests. Advances in clinical chemistry patient-based real-time quality control (PBRTQC). Questionable FSH Results in a 52-Year-Old Female with Amenorrhea. Impact of the loss of Laboratory Developed Mass Spectrometry testing at a major academic medical center. Review of SARS-CoV-2 Antigen and Antibody Testing in Diagnosis and Community Surveillance. An Opioid Hiding in Plain Sight: Loperamide-Induced False-Positive Fentanyl and Buprenorphine Immunoassay Results. Reevaluating the Icterus Index Cutoff of a Jaffe Creatinine Method. |
|